Stock Rating Downgrade
The Value Trend Rating for OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) weakened of late from B to C reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) stock increased 1.7% on 3/7/25. The shares closed at $300.48. Trading volume in this advance was normal. The stock has been strong relative to the market over the last nine months and has risen 3.6% during the last week.
Current PriceTarget Research Rating
VERISK ANALYTICS INC has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. VERISK ANALYTICS INC has a good Appreciation Score of 73 but a neutral Power Rating of 46, triggering the High Neutral Value Trend Rating.
Be the first to comment